Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease.
Curr Med Sci
; 43(1): 1-12, 2023 Feb.
Article
en En
| MEDLINE
| ID: mdl-36867358
ABSTRACT
Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the "expert consensus on the diagnosis and treatment of anticancer DILD" after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Enfermedades Pulmonares Intersticiales
Tipo de estudio:
Diagnostic_studies
/
Guideline
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Curr Med Sci
Año:
2023
Tipo del documento:
Article
País de afiliación:
China